Chicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRX

Chicago Partners Investment Group LLC purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 10,756 shares of the biopharmaceutical company’s stock, valued at approximately $535,000.

Other institutional investors have also added to or reduced their stakes in the company. Morgan Stanley grew its position in shares of Royalty Pharma by 25.2% during the 4th quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock valued at $2,135,790,000 after purchasing an additional 11,110,115 shares in the last quarter. Capital International Investors raised its holdings in Royalty Pharma by 14.3% during the 4th quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock valued at $1,201,870,000 after buying an additional 3,891,615 shares during the last quarter. Norges Bank purchased a new position in shares of Royalty Pharma in the fourth quarter valued at about $131,923,000. Qube Research & Technologies Ltd raised its stake in shares of Royalty Pharma by 737.3% during the third quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock valued at $87,557,000 after acquiring an additional 2,185,366 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Royalty Pharma by 379.2% during the third quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock valued at $78,855,000 after acquiring an additional 1,768,702 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insiders Place Their Bets

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the transaction, the director owned 191,803 shares in the company, valued at approximately $10,165,559. This represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the sale, the executive vice president directly owned 459,399 shares in the company, valued at approximately $25,965,231.48. The trade was a 17.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 427,800 shares of company stock valued at $23,333,723. 18.84% of the stock is currently owned by corporate insiders.

Royalty Pharma Trading Down 0.6%

NASDAQ RPRX opened at $58.18 on Friday. The stock has a market cap of $33.50 billion, a P/E ratio of 39.58, a P/E/G ratio of 10.30 and a beta of 0.43. The stock’s fifty day moving average price is $55.01 and its 200-day moving average price is $48.52. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $59.44. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. As a group, equities analysts forecast that Royalty Pharma PLC will post 5.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on RPRX shares. Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Morgan Stanley lifted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. JPMorgan Chase & Co. boosted their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Citigroup increased their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $56.57.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.